Maia Wealth LLC Acquires Shares of 14,396 ImmunityBio, Inc. (NASDAQ:IBRX)

Maia Wealth LLC acquired a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 14,396 shares of the company’s stock, valued at approximately $37,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Stephens Inc. AR purchased a new stake in shares of ImmunityBio during the 4th quarter worth approximately $26,000. Captrust Financial Advisors purchased a new stake in shares of ImmunityBio during the 3rd quarter worth approximately $41,000. Mutual Advisors LLC purchased a new stake in shares of ImmunityBio during the 4th quarter worth approximately $41,000. Crestwood Advisors Group LLC purchased a new stake in shares of ImmunityBio during the 4th quarter worth approximately $41,000. Finally, Virtu Financial LLC purchased a new stake in shares of ImmunityBio during the 3rd quarter worth approximately $51,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $2.85 on Tuesday. ImmunityBio, Inc. has a 1 year low of $2.28 and a 1 year high of $10.53. The company has a market capitalization of $1.99 billion, a P/E ratio of -3.10 and a beta of 0.94. The business has a 50 day moving average price of $3.02 and a 200 day moving average price of $3.73.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. As a group, research analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IBRX. BTIG Research began coverage on ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research note on Friday.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.